Send to

Choose Destination
Neuropsychopharmacology. 2017 Mar;42(4):844-853. doi: 10.1038/npp.2016.224. Epub 2016 Sep 29.

Adjunctive Lanicemine (AZD6765) in Patients with Major Depressive Disorder and History of Inadequate Response to Antidepressants: A Randomized, Placebo-Controlled Study.

Author information

Yale University School of Medicine, New Haven, CT, USA.
Sarkis Clinical Trials, Gainesville, FL, USA.
Northwest Clinical Research Center, Bellevue, WA, USA and Department of Psychiatry, Duke University School of Medicine, Durham, NC, USA.
Finger Lakes Clinical Research, Rochester, NY, USA.
Atlanta Center for Medical Research, Atlanta, GA, USA.
Welgemoed Medical Centre, Cape Town, South Africa.
iResearch Atlanta, Decatur, GA, USA.
Rush University Medical Center, Chicago, IL, USA.
Universidad de Antofagasta, Antofagasta, Chile.
AstraZeneca Pharmaceuticals LP, Wilmington, DE, and Cambridge, MA, USA.
Baylor College of Medicine, Houston and Michael E. Debakey VA Medical Center, Houston, TX, USA.


The objective of this study was to investigate the efficacy and safety of adjunctive lanicemine (NMDA channel blocker) in the treatment of major depressive disorder (MDD) over 12 weeks. This phase IIb, randomized, parallel-arm, double-blind, placebo-controlled study was conducted at 49 centers in four countries between December 2011 and August 2013 in 302 patients aged 18-70 years, meeting criteria for single episode or recurrent MDD and with a history of inadequate treatment response. Patients were required to be taking an allowed antidepressant for at least four weeks prior to screening. Patients were randomized equally to receive 15 double-blind intravenous infusions of adjunctive lanicemine 50 mg, lanicemine 100 mg, or saline over a 12-week course, in addition to ongoing antidepressant. The primary efficacy end point was change in Montgomery-Åsberg Depression Rating Scale (MADRS) total score from baseline to week 6. Secondary efficacy outcome variables included change in MADRS score from baseline to week 12, response and remission rates, and changes in Clinical Global Impression scale, Quick Inventory of Depressive Symptomology Self-Report score, and Sheehan Disability Scale score. Of 302 randomized patients, 240 (79.5%) completed treatment. Although lanicemine was generally well tolerated, neither dose was superior to placebo in reducing depressive symptoms on the primary end point or any secondary measures. There was no significant difference between lanicemine and placebo treatment on any outcome measures related to MDD. Post hoc analyses were performed to explore the possible effects of trial design and patient characteristics in accounting for the contrasting results with a previously reported trial.

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center